Biologics to Treat Substance Use Disorders: Vaccines, Monoclonal Antibodies, and Enzymes

ISBN-13: 9783319231495 / Angielski / Twarda / 2016 / 453 str.

Ivan D. Montoya

Opis

This book is a scientific compendium documenting the state of the art in the discovery and development of vaccines, monoclonal antibodies, and enzymes for the treatment of Substance Use Disorders (SUDs). The book gives detailed consideration to some of the most cutting edge topics in addiction medicine, including vaccines for nicotine, cocaine, heroin, and methamphetamine dependence; monoclonal antibodies against cocaine, methamphetamine, and phencyclidine; and the enzymes butyrylcholinesterase and cocaine esterase. In addition, the text covers a wide range of new strategies designed to optimize the development and efficacy of biologics. Unlike any other resource, this book reviews how biologics offer exciting new therapeutic opportunities for various psychiatric conditions. Written by experts in the field, Biologics to Treat Substance Use Disorders is as an authoritative reference for psychiatrists, psychologists, and all other medical professionals working with patients suffering from Substance Use Disorders.

Recenzje

"The intended audience is psychiatrists, pharmacologists, immunologists, counselors, toxicologists, social workers, addiction specialists, and all medical professionals working with patients with drug addictions. ... This is the first book, and a most comprehensive one, about the research and development of biologics to treat substance use disorders and overdose. Hopefully, biologics will be part of the therapeutic armamentarium that healthcare providers can use in the treatment of their patients with these disorders." (Michael Easton, Doody's Book Reviews, June, 2016)

Spis treści

Introduction

Biologics to Treat Substance Use Disorders: Vaccines, Monoclonal Antibodies, and Enzymes

Phil Skolnick

Section 1.  Vaccines

 

Therapeutic Vaccines for Treating Nicotine Addiction.

Matthew W. Kalnik, Ph.D.

Vaccines for Treating Cocaine Use Disorders

Coreen B. Domingo;  Daryl Shorter; Thomas R. Kosten  

Vaccines for Opioid Addiction

Michael Raleigh and Paul Pentel

Vaccines for Methamphetamine Use Disorder

Thomas R. Kosten and Therese A. Kosten

Vaccine for Cocaine Addiction and HIV infection

Timothy Cardozo, Sergey Shmelkov, Kenneth Ca

rr, John Rotrosen, Pedro Mateu-Gelabert, Samuel R. Friedman

Section 2. Monoclonal antibodies

Monoclonal Antibodies: Introduction

S. Michael Owens

Anti-cocaine monoclonal antibodies

Hanna N. Wetzel, William J. Ball and Andrew B. Norman                                                                       

Discovery and Development of an Anti-methamphetamine Monoclonal Antibody for use in Treating Methamphetamine Abuse

Michael D. Hambuchen, Misty W. Stevens, Melinda G. Gunnell, W. Brooks Gen-try, and S. Michael Owens

Section 3. Enzymes

Enzyme-based cocaine pharmacotherapies: Current status and projections for the future. 

James H. Woods, Chang-Guo Zhan

Viral gene transfer of enzymes

W. Steve Brimijoin Cocaine Hydrolases Designed from Butyrylcholinesterase

Fang Zheng and Chang-Guo Zhan                                                                                                                    

Section 4. Strategies to optimize the development of biologics to treat addictions

Adenovirus-Based Vaccines for the Treatment of Substance Use Disorders

David F. Havlicek, Jonathan B. Rosenberg, Dolan Sondhi, Ronald G. Crystal

and Stephen M. Kaminsky

Nanotechnology based nicotine vaccine

Petr O. Ilyinskii and Lloyd P.M. Johnston

Exploration of DNA nanostructures for rational design of vaccines

Xiaowei Liu, Sidney M. H

echt,  Hao Yan, Paul R. Pentel, and Yung Chang

Adjuvants for Substance Abuse Vaccines

 Frank M. Orson, Berma M. Kinsey, Muthu Ramakrishnan, Reetakshi Arora, Thomas R. Kosten

Skin Vaccination against Nicotine Addiction

Xinyuan Chen, Ji Wang, Jeffrey H. Wu, and Mei X. Wu

Hapten design for anti-addiction vaccine development

Karen C. Collins, Kim D. Janda

B cell mechanisms underlying vaccine efficacy against drugs of abuse

 Marco Pravetoni, Ph.D.

prave001@umn.edu

Section 5. Practical Considerations

Practical considerations for the development of vaccines against drugs of abuse

Oscar B. Torres, Carl R. Alving, Arthur E. Jacobson, Kenner C. Rice and

Gary R. Matyas

Ethical Aspects of Biologics to Treat Substance Use Disorders

Ivan D. Montoya

 

O autorze

Ivan D. Montoya

National Institutes of Health, 

Bethesda, USA